An in vivo enhancement of mesothelin-targeting rITs by paclitaxel has been described in xenograft models of solid tumors including the mesothelin-expressing pancreatic cancer cell line KLM-1 [28], breast cancer cell line HCC-70, gastric cancer cell line MKN-28 [29], and the cervical cancer cell line KB [31]. Here, MSLN is linked to breast cancer.